BioSight
Companies
Cabaletta Bio, Inc. logo

CABA

NASDAQPHILADELPHIA, PA
Cabaletta Bio, Inc.

Cabaletta Bio is a clinical-stage biotech company developing CAR-T cell therapies, which are engineered immune cells designed to treat disease. Its lead program, resecabtagene autoleucel (rese-cel), is currently in Phase 1/2 testing under a trial called RESET for autoimmune conditions. The company relies on third-party manufacturers and licensed intellectual property to advance its pipeline and will require significant additional funding to complete clinical development.

Price history not yet available for CABA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar